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The preparation and characterization of the new 3,5-diacetyl-1,2,4-triazol bis(4-cyclohexyl
thiosemicarbazone) ligand, H5L
1, is described. Treatment of H5L
1 with K2PtCl4 gave the dinuclear
complex [Pt(H3L
1)]2, 1, but using MCl2(PPh3)2 where M = Pd or Pt, mononuclear complexes 2 and 3,
of general formula [M(H3L
1)PPh3], were obtained. Subsequent reaction of the [Pd(H3L
1)PPh3] complex
with PdCl2(PPh3)2 yielded a new dinuclear complex [(PPh3)Pd(H2L
1)PdCl], 4. All compounds have
been characterized by elemental analysis and FAB+ spectrometry and by IR and NMR spectroscopy.
The molecular structures of mononuclear complexes 2 and 3 and dinuclear complex 4 have been
determined by X-ray crystallography. The new compounds synthesized have been evaluated for
antiproliferative activity in vitro against NCI-H460, HepG2, MCF-7, A2780 and A2780cisR human
cancer cell lines. The cytotoxicity data suggest that the H5L
1 ligand and [Pt(H3L
1)]2, complex 1, may be
endowed with important cytotoxic properties since they are capable of not only circumventing cisplatin
resistance in A2780cisR but also exhibit antiproliferative activity in NCI-H460. The interactions of these
compounds with calf thymus DNAwere investigated by UV-vis absorption and a nephrotoxic study, in
LLC-PK1 cells, has also been carried out.
Introduction
The synthesis of preorganized dinuclear transition metal com-
plexes is a ﬁeld of research that has been rapidly growing for the
past few years. Scaffolds to support and control a bimetallic
arrangement may be provided by compartmental binucleating
ligands that host two metal ions in suitable proximity.1–5
Among the ligands that are capable of positioning two metal
centers in close proximity, aromatic ﬁve-membered heterocycles
containing two or three nitrogen atoms appear to be particularly
suitable candidates. 1,2,4-Triazole-based ligands with chelating
side arms in the 3- and 5-positions of the heterocycle are
especially valuable for this purpose since the 1,2,4-triazole has a
high tendency to span two metal ions, and the individual co-
ordination spheres, as well as the metal–metal separations, can
be tuned by appropriate alterations of the appended chelate
substituents.6,7
Such polydentate ligands quite often are Schiff bases (or the
related reduced derivatives), obtained by condensation of appro-
priately designed and prepared formyl- (or keto-) and primary
amine precursors.8–11 Thiosemicarbazones (>CvN–NH–C(S)–
N<) are an important class of Schiff base ligands that are structu-
rally interesting, since both sulfur and nitrogen atoms may be
involved in the coordination, thus invoking the a or b character
of the metallic centre.12–15
In this line, we have been employing the diketone heterocycle
3,5-diacetyl-1,2,4-triazole in condensation reactions with a series
of thiosemicarbazides to obtain ligands containing two thiosemi-
carbazone moieties separated by the ﬁve-membered heterocycle
ring 1,2,4-triazol which have been shown to be versatile poly-
dentate ligands towards metal ions with square planar co-
ordination geometry. Depending on the participation of the
central ring in the coordination (monodentate N1/N2 versus
N1N2 bridging mode) we could synthesize and characterize both
dimers [2 + 2] helicates and tetranuclear compounds probing the
dinucleating tendency of these triazol/bis(thiosemicarbazone)
ligands (Fig. 1).16–19
A factor of importance in the synthesis of compounds with
1,2,4-triazole is the ease of formation of the triazolate ion by
deprotonation. The 1,2,4-triazolate anion can bind metal ions
through different coordination modes, as is depicted in
Scheme 1.
N1N4 Bridging is relatively rare compared with N1N2 brid-
ging, this is probably because when both hydrazine-type
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nitrogen atoms are bound to metal ions, the N4 easily acts as a
hydrogen acceptor providing additional stability. In fact, in
addition to the ligand–metal interactions, hydrogen bonding
plays aQ5 highly important role in the geometry of the coordination
compounds of these ligands.20
On the other hand many α-N-heterocyclic thiosemicarbazones
have been reported to exert tumor-inhibiting effects and one of
the most promising 3-aminopyridine-2-carboxaldehyde thiosemi-
carbazones (Triapine®) has entered several phase I and II clini-
cal trials.21–23 Also, phosphines and phosphine metal containing
complexes are of current interest due to their potential use as
antitumor agents. Particularly, 1,2-bis(diphenylphosphino)ethane
and some of its analogues have been shown to have antitumor
activity against a wide range of tumors, and moreover, their
activity is enhanced upon coordination to metal ions, such as
gold(I).24
Recently, investigations from our laboratory have led to the
development of the ﬁrst mononuclear Pd(II) complexes derived
from 3,5-diacetyl-1,2,4-triazol bis(4-monosubstituted thiosemi-
carbazones) bearing triphenylphosphine as a coligand. Their
excellent antiproliferative activity was demonstrated by in vitro
experiments in various human cell lines derived from different
types of solid tumours.25
An X-ray structural study demonstrated that 3,5-diacetyl-
1,2,4-triazol bis(4-monosubstituted thiosemicarbazone) ligands
act as tridentate dianion binding Pd(II) ions via one Ntriazolic and
Niminic and S donor atoms from one thiosemicarbazone arm.
Therefore some of the ligand donor atoms are still free and thus
the presence of uncoordinated donor atoms and their relative dis-
positions in space suggested that such complexes might provide
a possibility to bind to a second metal ion.
Keeping in view the above observations, it was planned to
construct a series of dinuclear N1N4triazol-bridged metal
complexes based on 3,5-diacetyl-1,2,4-triazol bis(4-monosubsti-
tuted thiosemicarbazone) triphenylphosphine palladium(II) pre-
cursors. Herein, we report on the synthesis and characterization
of the new 3,5-diacetyl-1,2,4-triazol bis(4-cyclohexyl thiosemi-
carbazone) ligand together with the study of its complexation
potential for Pd(II) and Pt(II) ions (Scheme 2).
The cytotoxic activity of the new compounds synthesized and
cisplatin (assumed as the reference antitumor drug) against ﬁve
human cancer cell lines, NCI-H460 (non-small cell lung cancer),
HepG2 (hepatocellular carcinoma), MCF-7 (breast cancer),
A2780 and A2780cisR (epithelian ovarian cancer), has been
studied. The interaction of these compounds with calf thymus
DNA (CT-DNA) was also investigated. In addition toxicity
studies, on normal renal LLC-PK1 cells, have been carried out
as an attempt to provide an insight into the pharmacological
properties of these compounds.
The present work aims to contribute to the understanding of
the structural and cytotoxic characteristics of these compounds.
Results and discussion
Synthesis and spectroscopic characterization
A new multidentate ligand, H5L
1, which possesses two NNS
coordination sites was synthesized as a platform for metal
arrangement. Complexation with [MCl4]
2− ions (M = Pd or Pt)
resulted in the formation of dimers [2 + 2] helicates, in which
each triazol-bis(thiosemicarbazone) behaves as a dianionic
ligand with deprotonation of one hydrazinic (2NH) and the
triazol ring protons and [NNSS] donor set.
Since the cleavage of binuclear Pd(II) and Pt(II) complexes
with tertiary phosphines is well known26 we decided to examine
the behavior of the dimers [2 + 2] helicates synthesized. So, sub-
sequent treatment of both palladium and platinum dimers with
PPh3, in 1 : 2 molar ratios, yielded the expected mononuclear
complexes in which each metal atom is coordinated to a phos-
phine ligand. Interestingly, reaction of the H5L
1 ligand with
MCl2(PPh3)2 salts (M = Pd or Pt) in toluene, in the presence of
Scheme 1 Schematic representation of the 1,2,4-triazole geometry and
three types of coordination modes of the 1,2,4-triazolate anion.
Fig. 1 Capped sticksQ4 representation of both dimer [2 + 2] helicate
(left) and tetranuclear (right) Pd(II) complexes derived from 3,5-diacetyl-
1,2,4-triazol bis(4ethyl thiosemicarbazone).
Scheme 2 Structure of the 3,5-diacetyl-1,2,4-triazol bis(4-cyclohexyl
thiosemicarbazone) ligand and its metal complexes synthesized.
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triethylamine base, in 1 : 1 molar ratios afforded the same mono-
nuclear complexes of stoichiometry [M(H3L
1)PPh3].
Once the mononuclear complexes were obtained, the presence
of several potential uncoordinated donor atoms and their relative
dispositions in space suggested that such complexes might
provide a possibility to bind to a second metal ion. So, upon the
addition of MCl2(PPh3)2 to the [M(H3L
1)PPh3] precursors, we
have achieved the synthesis of a new dinuclear complex, in
which the triazol/bis(thiosemicarbazone) ligands have been
found to coordinate two metal ions as a symmetric trianionic
hexadentate ligand with deprotonation of the two hydrazinic
(2NH) and the triazol ring protons. It may be pointed out here
that the two metal ions contain different coordination spheres
[NNSP] and [NNSCl].
The compounds described in this paper were characterized by
elemental analysis and FAB+ spectrometry and by IR, 1H NMR
and 31P NMR spectroscopy (the signiﬁcant IR vibrational bands
and the 1H chemical shift values are listed in the Experimental
section). The infrared spectral bands most useful for determining
the mode of coordination of the ligands are the ν(CvN) iminic
and ν(CvS) thioamide IV vibrations. These bands shift to lower
wavenumbers in the spectra of the complexes suggesting co-
ordination of the imine nitrogen and sulfur atoms. In complexes
2, 3 and 4, the presence of the triphenylphosphine ligand is
conﬁrmed by the existence of the characteristic bands around
3050 and 1097 cm−1 for ν(CH) and ν(P–C), with no signiﬁcant
change when compared to the precursor PdCl2(PPh3)2.
In the 1H NMR spectrum, the free ligand shows various peaks
at low ﬁelds: δ ∼ 15 ppm assigned to the triazolic proton,
δ ∼ 12 ppm assigned to the hydrazinic protons (2NH) and
δ ∼ 10 ppm assigned to the thioamidic protons (4NH). In the
dimeric complex 1 as well as in mononuclear Q6complexes 2 and
3, the absence of any signals above 15 ppm, indicative of de
deprotonation of the triazole ring, together with the presence of
only one signal assigned to 2N hydrazinic hydrogens is consist-
ent with the asymmetric di-deprotonation typical of 3,5-diacetyl-
1,2,4-triazol bis(thiosemicarbazone) ligands. However both the
signals assigned to the triazolic proton and the hydrazinic
protons were absent in the spectrum of complex 4, thus conﬁ-
rming the symmetric tri-deprotonation of the ligand.
31P NMR spectroscopy was used to further conﬁrm complexa-
tion of the ligand. Palladium complexes 2 and 4 display a singlet
at 32.75 and 29.00 ppm respectively for the phosphorus atom of
the triphenylphosphine ligand, while the platinum derivative 3
displays typical resonance at 11.20 ppm.
Description of mononuclear crystal structures 2 and 3
[Pd(H3L
1)PPh3]·EtOH and [Pt(H3L
1)PPh3]·EtOH were iso-
lated as neutral compounds. The most signiﬁcant parameters for
these complexes are shown in Table 1.
The structures together with the atom labelling schemes are
shown in Fig. 2 and 3. Both compounds are isostructural, hence
displaying nearly identical cell parameters, crystallize in the tri-
clinic P1ˉ space group with Z = 2 and the asymmetric units contain
one molecule of the neutral complex and one ethanol molecule
(for compound 2 the H atoms of the EtOH molecule were not
located in the Fourier difference map). The metal ion presents
a square planar geometry the bis(thiosemicarbazone) ligand
Table 1 Crystal data and structure reﬁnement for 2, 3 and 4 complexesQ7
2 3 4
Molecular formula C40H46N9OPPdS2 C40H52N9OPPtS2 C45H62ClN9OPPd2S3
Formula weight 870.35 963.07 1120.44
Temperature (K) 100(2) 100(2) 100(2)
Wavelength (Å) 0.71073 0.71073 1.54178
Crystal system Triclinic Triclinic Monoclinic
Space group P1ˉ P1ˉ P2(1)/n
a (Å) 10.7402(7) 10.769(5) 12.4247(4)
b (Å) 11.8911(7) 12.054(5) 16.3391(5)
c (Å) 17.4118(12) 17.499(8) 24.2489(8)
α (°) 81.039(4) 81.09(2) 90
β (°) 89.542(4) 89.09(2) 92.702(2)
γ (°) 70.946(3) 70.974(19) 90
Volume (Å3) 2074.0(2) 2120.1(16) 4917.3(3)
Z 2 2 4
Density (calculated)
(g cm−3)
1.394 1.509 1.513
Absorption coefﬁcient (mm−1) 0.630 3.488 8.247
F(000) 900 972 2300
Crystal size (mm3) 0.15 × 0.10 × 0.05 0.30 × 0.34 × 0.38 0.20 × 0.15 × 0.13
Index ranges −13 ≤ h ≤ 13, −14 ≤ k ≤ 14,
−21 ≤ l ≤ 21
−13 ≤ h ≤ 13, −15 ≤ k ≤ 13,
−22 ≤ l ≤ 21
−14 ≤ h≤ 14, −19 ≤ k ≤ 19,
−29 ≤ l ≤ 29
Reﬂections collected 49 659 51 305 30 211
Independent reﬂections 8437 [R(int) = 0.0644] 8787 [R(int) = 0.0555] 9122 [R(int) = 0.0340]
Data/restraints/parameters 8437/0/499 8787/0/485 9122/11/569
Goodness-of-ﬁt on F2 1.129 1.115 1.039
Final R indices [I > 2σ(I)] R1 = 0.0432, wR2 = 0.1129 R1 = 0.0340, wR2 = 0.1123 R1 = 0.0412, wR2 = 0.1105
R indices (all data) R1 = 0.0652, wR2 = 0.1373 R1 = 0.0462, wR2 = 0.1584 R1 = 0.0459, wR2 = 0.1148
Largest diff. peak and hole (e Å−3) 1.555 and −0.585 2.609 and −3.968 2.164 and −0.727
a
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being attached through the Ntriazolic, and the Niminic and S atoms
from one thiosemicarbazone arm. The fourth coordination posi-
tion is occupied by a P atom from the PPh3 coligand which is
coordinated to Pd or Pt trans to Niminic.
The bis(thiosemicarbazone) ligand is in dianionic form
showing Z, E conﬁguration, that is the coordinated thiosemi-
carbazone arm, involved in two ﬁve-membered (PdSCNN and
PdNCCN or PtSCNN and PtNCCN) chelate rings, with the
sulfur atom cis to the azomethine nitrogen atom, and the unco-
ordinated thiosemicarbazone arm with the S atom trans to the
azomethine nitrogen atom. This arrangement is reinforced by
intramolecular hydrogen bonds between the 2NH of the unco-
ordinated thiosemicarbazone arm and one triazole nitrogen atom.
It is important to note that upon coordination, the deproto-
nated arm undergoes signiﬁcant evolution from the thione to the
thiol form which is reﬂected in a C–S distance of 1.786(6) Å for
2 and 1.776(5) Å for 3 while the neutral thiosemicarbazone arm
presents a shorter C–S bond length [1.668(6) for 2 and 1.693(6) Å
for 3]. The C–N and N–N bond distances (Tables 2 and 3) are
intermediate between formal single and double bonds, pointing
to extensive delocalization over the entire 3,5-diacetyl-1,2,4-tri-
azole bis(thiosemicarbazone) skeleton, however metal co-
ordination provokes an important shortening of the C–Nhydrazinic
distance in the deprotonated arm as compared to the undeproto-
nated arm.
Inspection of the angles formed between the metal ion
(M = Pd2+, Pt2+) and the coordinated atoms shows that the metal
is contained within a slightly distorted square-planar environ-
ment. The distortion is caused by the restricted bite angle of the
tridentate ligand as reﬂected in the N(3)–M(1)–N(4) and N(3)–
M(1)–S(1) angles (less than 90°). The angles S(1)–M(1)–P(1)
and P(1)–Pd(1)–N(4) are therefore greater than 90°.
Within each molecule, the bis(thiosemicarbazone)–metal
moiety is close to planar, this disposition appears to be favored
by the presence, at the not coordinated thiosemicarbazone arm,
Fig. 3 Molecular structure of complex 3, hydrogen atoms are omitted
for clarity.
Fig. 2 Molecular structure of complex 2, hydrogen atoms are omitted
for clarity.
Table 2 Selected bond distances (Å) and angles (°) for Pd(II)
complexes 2 and 4
2 4
S(1)–C(1) 1.774(4) 1.781(4)
S(2)–C(6) 1.681(4) 1.763(4)
C(1)–N(1) 1.338(5) 1.329(6)
C(1)–N(2) 1.307(5) 1.314(5)
C(2)–N(3) 1.280(5) 1.302(5)
C(3)–N(4) 1.338(5) 1.349(5)
C(3)–N(6) 1.333(5) 1.341(5)
C(4)–N(5) 1.339(5) 1.331(5)
C(4)–N(6) 1.354(5) 1.373(5)
C(5)–N(7) 1.288(4) 1.300(5)
C(6)–N(8) 1.354(5) 1.312(5)
C(6)–N(9) 1.315(5) 1.347(5)
C(7)–N(1) 1.456(5) 1.475(6)
N(2)–N(3) 1.372(4) 1.368(5)
N(4)–N(5) 1.349(4) 1.344(5)
N(7)–N(8) 1.377(4) 1.375(5)
Pd(1)–S(1) 2.2434(10) 2.2578(9)
Pd(1)–N(3) 2.026(3) 2.032(3)
Pd(1)–N(4) 2.031(3) 2.037(3)
Pd(1)–P(1) 2.2436(10) 2.2689(10)
N(3)–Pd(1)–N(4) 79.72(12) 79.29(13)
N(3)–Pd(1)–S(1) 84.00(9) 84.00(9)
N(3)–Pd(1)–P(1) 178.09(10) 171.40(9)
N(4)–Pd(1)–S(1) 163.71(9) 163.27(10)
N(4)–Pd(1)–P(1) 101.19(9) 97.56(10)
S(1)–Pd(1)–P(1) 95.07(4) 98.90(4)
N(6)–Pd(2)–N(7) 81.16(12)
N(6)–Pd(2)–S(2) 165.05(9)
N(6)–Pd(2)–Cl(1) 104.92(9)
N(7)–Pd(2)–S(2) 84.05(10)
N(7)–Pd(2)–Cl(1) 172.98(10)
S(2)–Pd(2)–Cl(1) 98.90(4)
Table 3 Selected bond distances (Å) and angles (°) for Pt(II) complex 3
S(1)–C(1) 1.775(6) N(3)–Pd(1)–N(4) 79.3(1)
S(2)–C(6) 1.692(7) N(3)–Pd(1)–S(1) 84.0(1)
C(1)–N(1) 1.352(6) N(3)–Pd(1)–P(1) 171.4(1)
C(1)–N(2) 1.311(8) N(4)–Pd(1)–S(1) 163.3(1)
C(2)–N(3) 1.288(8) N(4)–Pd(1)–P(1) 97.6(1)
C(3)–N(4) 1.340(7) S(1)–Pd(1)–P(1) 98.90(4)
C(3)–N(6) 1.330(7)
C(4)–N(5) 1.346(7)
C(4)–N(6) 1.370(7)
C(5)–N(7) 1.286(7)
C(6)–N(8) 1.367(7)
C(6)–N(9) 1.331(6)
C(7)–N(1) 1.453(8)
N(2)–N(3) 1.397(6)
N(4)–N(5) 1.355(5)
N(7)–N(8) 1.386(8)
Pt(1)–S(1) 2.259(2)
Pt(1)–N(3) 2.027(6)
Pt(1)–N(4) 2.037(4)
Pt(1)–P(1) 2.245(2)
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of an intramolecular hydrogen bond between the hydrazinic
hydrogen and one triazolic nitrogen atom. So the supramolecular
association involves π–π stacking interactions between
parallel layers of molecules. It is suggested that ethanol solvent
molecules link adjacent units of the complex via intermolecular
hydrogen bonds.
Description of dinuclear crystal structure 4
The molecular structure of the [(PPh3)Pd(H2L
1)PdCl] complex,
which crystallized with one DMSO molecule and one pentane
solvent molecule in the monoclinic P2(1)/n space group,
together with the atom labelling scheme is shown in Fig. 4. The
most characteristic feature is the linear arrangement of the two
Pd(II) ions, which are bridged by the triply deprotonated ligand.
Crystallographic data are shown in Table 1 with selected bond
lengths and angles shown in Table 2.
The 3,5-diacetyl-1,2,4-triazol bis(4-cyclohexyl thiosemicarba-
zone) ligand behaves as a trianion bridging the two metal ions
through the two not adjacent nitrogen atoms of the central tri-
azole ring. So, the ligand coordinates to the Pd(1) center via:
triazolic nitrogen atom N(4), iminic nitrogen N(3) and sulfur
atom S(1); the coordination sphere is completed by the phos-
phorus atom from the PPh3 coligand. The other palladium atom,
Pd(2), is coordinated to the remaining triazolic nitrogen N(6),
iminic nitrogen N(7) and sulfur S(2) atoms of the ligand being
the fourth position occupied by a terminal chlorido ligand.
The geometry around the palladium atoms is square-planar
with slight distortions from ideal values according to the
observed trans bond angles N–Pd–S and N–Pd–P or N–Pd–Cl.
This may be attributed to the restricted bite angle of the triden-
tate moieties.
The Pd–N and Pd–S bond distances in the range 1.9947(3)–
2.151(3) Å and 2.291(10)–2.2578(9) Å, respectively, are com-
parable with those reported for Pd(II) thiosemicarbazone com-
plexes.27 The C–S bond lengths of 1.681(4) and 1.781(4) Å are
within the normal range of a C–S single bond, indicating that the
thiosemicarbazone moieties adopt the thiol tautomeric form.
The C–N and N–N bond distances are intermediate between
formal single and double bonds, pointing to extensive
delocalization over the entire 3,5-diacetyl-1,2,4-triazole bis(thio-
semicarbazone) skeleton.
In compound 4 intramolecular hydrogen bonding interactions
are not observed and intermolecular hydrogen bonding is limited
to N(1)–H(1)⋯O(1) with a contact distance of 2.85 Å and
<(NHO) angle 62.1°.
Antiproliferative activity against tumor and normal cells
Cisplatin, cis-diamminedichloridoplatinum(II), and its analogs
are among the most effective agents for the treatment of cancer.
However its restricted clinical utility, due to the frequent deve-
lopment of drug resistance, the limited spectrum of tumors
against which these drugs are active and severe normal tissue
toxicity, has generated new areas of research, which mainly
focused on the search for new compounds with low toxicity and
improved therapeutic properties.28–32
To assess the antitumor potential of the newly synthesized
compounds, its antiproliferative activity (in powder solid form)
was tested in vitro against a panel of human cancer cell lines
containing examples of lung (NCI-H460), breast (MCF-7), liver
(Hep-G2) and ovarian (A2780 and A2780cisR) cancers. For
comparison purposes the cytotoxicity of cisplatin was always
evaluated under the same experimental conditions (Table 4).
Out of an initial screening of the ﬁve compounds synthesized,
two of them presented relevant antiproliferative actions, with IC50
values in the low µM range. The remaining compounds show, at
100 µM concentration, very low cellular growth inhibition (<50%)
and therefore had no evaluable cytotoxicity (IC50 > 100 µM).
In particular, this study identiﬁed both the free ligand H5L
1
and the [Pt(H3L
1)]2 dimer complex, 1, as having antiproliferative
activity in the low-micromolar range, against ovarian (A2780,
cisplatin sensitive, and A2780cisR, cisplatin resistant) and lung
(NCI-H460) cancer cells. The ligand also exhibits antiprolifera-
tive activity against breast (MCF-7) cancer cells.
Of particular relevance are the values of the resistance factor,
RF (deﬁned as IC50 in A2780cisR/IC50 in A2780), since both
compounds tested have a much better RF than cisplatin. This
observation may suggest that these compounds are able to cir-
cumvent cisplatin resistance and this is probably due to a differ-
ent mechanism of action. In fact, it has been demonstrated
that the main molecular target of α-(N)-heterocyclic thiosemi-
carbazones is the ribonucleotide reductase (RR), one of the most
complex enzymes in the cell, from a biological, structural and
regulatory point of view.33,34
Moreover, since one of the mechanisms of cisplatin induced
nephrotoxicity is the inactivation of some enzymes because of
the reaction between platinum ions and sulfur containing pro-
teins, the compounds reported here, bearing nitrogen and sulfur
atoms in their structure, could prevent the adverse reaction
described.35,36
In order to investigate this possible side effect, the compounds
investigated and cisplatin were subsequently tested, in vitro, in
the same μM range (1–100), on normal renal LLC-PK1 cells.
As is shown in Table 5, the H5L
1 ligand exhibits very low cellu-
lar growth inhibition (<50%), at the maximum concentration
of 100 μM, and therefore had no evaluable cytotoxicity
(IC50 > 100 μM). In addition, complex 1 was demonstrated to be
Fig. 4 Molecular structure of complex 4, hydrogen atoms are omitted
for clarity.
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much less toxic (about 5-fold) to the LLC-PK1 cells than cispla-
tin by comparing their IC50.
DNA binding studies
To study the binding afﬁnity between DNA and the new com-
pounds H5L
1 and 1, which have a signiﬁcant effect against the
tested cell lines, UV absorption spectroscopy has been a very
useful technique because the typical B-form DNA gives rise to a
characteristic band at 260 nm in the UV region. Hyperchromism
(increase in absorption of the DNA band) and hypochromism
(decrease in absorption of the DNA band) are the spectral
changes typical of a compound interaction with the DNA helix.
Hypochromism results from contraction of the DNA helix as
well as changes in its conformation, while hyperchromism
results from damage to the DNA double helix structure.37
In UV experiments, the spectra of CT-DNA in the presence of
each compound have been recorded, by keeping constant
CT-DNA concentration in diverse [CT-DNA]/[compound] mixing
ratios (R = 0.5–1.5) and monitoring the change in the absorption
intensity of the typical CT-DNA spectral band at 260 nm.
In the absence of CT-DNA, both compounds displayed intense
absorptions bands in the UV region (λmax 320–350 nm) assigned
to the intraligand π → π* transition of aromatic chromophores
which are also sensitive to their interaction with CT-DNA.
For both compounds, the absorption spectra display an
increase in the intensity of the characteristic CT-DNA absor-
bance while increasing the compound concentration (Fig. 5)
where the percentage of hyperchromism observed [% hyper-
chromism = (ADNA bound − ADNA free)/ ADNA bound] is about 38%
for the H5L
1 ligand and 43% for complex 1.
These characteristics suggest noncovalent interactions such as
electrostatic and surface (major or minor groove) binding along
outside of the DNA helix. Intercalative DNA-binding has been
excluded on the basis of the absence of hypochromism; on the
other hand both the ligand and the platinum(II) complex show
similar UV absorption proﬁles, therefore a covalent interaction
between Pt(II) and guanine N7 is unlikely.
Experimental
Measurements
Elemental analyses were performed on a LECO CHNS-932
microanalyzer. Fast atom bombardment (FAB) mass spectra
Table 4 In vitro antiproliferative activity of H5L
1, 1, and cisplatin, evaluated in several human cancer cell lines
Compound
IC50
a (μM)
RF
A2780 A2780cisR NCI-H460 MCF-7 Hep-G2 IC50(A2780cisR)/IC50(A2780)
H5L
1 32 ± 1 47 ± 1 49 ± 3 54 ± 1 >100 1.46
1 6.7 ± 0.04 8.99 ± 0.02 19 ± 2 >100 >100 1.34
Cisplatin 0.54 ± 0.02 3.7 ± 0.1 3.98 ± 0.2 8.75 ± 0.35 3.23 ± 0.06 6.85
a 50% inhibitory concentrations in the sulforhodamine B assay (48 h exposure for NCI-H460 and Hep-G2 and 96 h exposure for A2780, A2780cisR
and MCF-7). The compounds were tested in 1 : 99 DMSO–PBS solutions. Values are the means ± standard deviations obtained from at least three
independent experiments.
Table 5 In vitro antiproliferative activity of H5L
1, 1, and cisplatin,
evaluated in normal LLC-PK1 renal cells
Compound
IC50
LLC-PK1
H5L
1 >100
1 33 ± 1
Cisplatin 7.03 ± 0.08
Fig. 5 UV absorption spectra of CT-DNA in the absence and presence
of compounds H5L
1 (top) and 1 (bottom). The data were collected for
[CT-DNA] = 1.25 × 10−4 M and mixing ratio R = 0.5–1.5 (from top to
bottom).
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were performed on a VG AutoSpec spectrometer (nitrobenzyl
alcohol matrix). Nuclear Magnetic Resonance (NMR) spectra
were recorded on a BRUKER AMX-300 spectrometer. All cited
physical measurements were obtained by the Servicio Inter-
departamental de Investigación (SIDI) of the Universidad
Autónoma de Madrid.
Infrared spectra (KBr pellets) were recorded on a Bomen–
Michelson spectrophotometer (4000–400 cm−1). Electronic
spectra were recorded on a Thermo Scientiﬁc Evolution 260 Bio
UV-visible spectrophotometer.
Materials
Solvents were puriﬁed and dried according to standard pro-
cedures. Hydrazine hydrate, L-lactic acid, cyclohexyl isothio-
cyanate, palladium(II) chloride, potassium tetrachloridoplatinate(II)
and triphenylphosphine were commercially available.
Synthesis of compounds
3,5-Diacetyl-1,2,4-triazol bis(4-cyclohexylthiosemicarbazone)
ligand, H5L
1. An ethanolic solution of hydrazine hydrate
(0.250 g, 5 mmol) was added dropwise with constant stirring to
an ethanolic solution of cyclohexyl isothiocyanate (0.706 g,
5 mmol). The reaction mixture was stirred for one more hour and
then the white product 4-cyclohexylthiosemicarbazide formed
was ﬁltered, washed with cold ethanol and diethyl ether, dried
in vacuo and recrystallized from ethanol. A methanolic solution
of the 4-cyclohexylthiosemicarbazide (0.346 g, 2 mmol) was
then reﬂuxed with 3,5-diacetyl-1,2,4-triazol (0.153 g, 1 mmol),
which was prepared as described in the bibliography,38 for 5 h
and then was left to stand to ambient temperature. The solution
was reduced to half volume and the pale yellow solid formed
was ﬁltered, washed with cold ethanol and diethyl ether and
dried in vacuo.
Yield (55%), mp 205 °C. Elemental analysis found, C, 51.70;
H, 7.20; N, 26.95; S, 13.50; C20H33N9S2 requires C, 51.85; H,
7.15; N, 27.20; S, 13.80%. MS (FAB+ with mNBA matrix) m/z
464.3 (100%) for [C20H33N9S2 + H]
+. IR (KBr pellets): n/cm−1
3323 (s, NH-triazol), 3226 and 3099 (w, 2NH and 4NH), 1547
(s, CN), 853 (w, CS-thioamide IV band). 1H NMR
(300.14 MHz, DMSO-d6): d (ppm) 15.29 (s, NH-triazol, 1H),
12.57 and 10.75 (s, 2NH, 1H), 8.37, 8.34 and 8.20, 8.17 (d,
4NH, 1H), 4.30 (s, CH-cyclohexyl, 2H), 2.38 and 2.37 (s, CH3-
triazol, 3H), 1.91 (m, CH2 equatorial-cyclohexyl, 10H), 1.35 (m,
CH2 axial-cyclohexyl, 10H).
[M(H3L
1)]2. Dinuclear [2 + 2] dimer complexes were
obtained by reacting a methanol suspension of the 3,5-diacetyl-
1,2,4-triazol bis(4-cyclohexylthiosemicarbazone) ligand with a
methanolic solution of lithium tetrachloridopalladate(II) (0.140 g,
0.5 mmol) or a water solution of potassium tetrachloridoplatinate(II)
(0.207 g, 0.5 mmol). The reaction mixture was stirred for 5 h at
room temperature and the resulting orange solid obtained
ﬁltered, washed with methanol and diethyl ether, and dried
in vacuo. The difﬁculty experienced in crystallizing the palla-
dium complex because of its lower solubility resulted in less
satisfactory analyses. For M = Pt the crude mass was crystallized
from ca. 20 mL of DMSO to give pure [Pt(H3L
1)]2, 1.
Yield (32%), mp 228 °C (decomposes). Elemental analysis
found, C, 29.70; H, 5.70; N, 15.90; S, 8.20; C40H62N18S4Pt2·
16H2O requires C, 30.00; H, 5.90; N, 15.70; S, 8.00%. MS
(FAB+ with mNBA matrix) m/z 1313.4 for [{Pt(H3L
1)}2 + H]
+.
IR (KBr pellets): n/cm−1 3245 (w, 4NH), 2929, 2853 (s, CH),
1549 (s, CN). 1H NMR (300.14 MHz, DMSO-d6): d (ppm)
12.30 (s, 2NH, 1H), 9.28–8.80, 8.50–7.90 (m, 4NH, 2H), 3.95
(s, CH-cyclohexyl, 2H), 2.37 (s, CH3-triazol, 6H), 1.90–1.75
(m, CH2 equatorial-cyclohexyl, 10H), 1.40–1.20 (m, CH2 axial-
cyclohexyl, 10H).
Attempts to grow crystals of [Pt(H3L
1)]2 for X-ray analysis
were unsuccessful.
[Pd(H3L
1)PPh3], 2. This complex was obtained by reaction of
PdCl2(PPh3)2 metallic salt (0.351 g, 0.5 mmol), prepared by a
previously described procedure,39 with the 3,5-diacetyl-1,2,4-
triazol bis(4-cyclohexylthiosemicarbazone) ligand (0.232 g,
0.5 mmol) in toluene, in the presence of Et3N, in 1 : 1 molar
ratios. The reaction mixture was stirred for 2 h at room temp-
erature. The resulting orange solution was ﬁltered and left to stand
at ambient temperature for two days. The yellow-orange micro-
crystalline solid formed was ﬁltered, washed several times with
hot water, recrystallized from ethanol and ﬁnally dried in vacuo.
Yield (73%), mp 176 °C. Elemental analysis found, C, 55.30;
H, 5.60; N, 14.90; S, 7.55; C38H46N9S2PPd requires C, 55.00;
H, 5.55; N, 15.20; S, 7.70%. MS (FAB+ with mNBA matrix)
m/z 830.4 for [Pd(H3L
1)PPh3 + H]
+. IR (KBr pellets): n/cm−1
3213 (s, NH); 2927, 2851 (s, CH), 1523 (s, CN), 859
(w, CS-thioamide IV band). 1H NMR (300.14 MHz, DMSO-d6):
δ (ppm) 12.70 (s, 2NH, 1H); 8.30–8.25 (d, 4NH, 2H), 8.05–7.80
(m, aromatic protons, 15H); 4.45 and 4.40 (s, CH-cyclohexyl,
1H), 2.90 and 2.75 (s, CH3-triazol, 3H), 1.90 (m, CH2 equatorial-
cyclohexyl, 10H), 1.50 (m, CH2 axial-cyclohexyl, 10H).
31P
NMR (121.50 MHz, CDCl3): δ (ppm) 32.75 (PPh3).
Crystallization in ethanol allowed us to isolate single orange
crystals, which were studied by X-ray diffraction techniques.
[Pt(H3L
1)PPh3], 3. This complex was obtained by two differ-
ent routes.
Method 1: using the same procedure as for compound 2,
namely by reaction of PtCl2(PPh3)2 metallic salt (0.395 g,
0.5 mmol), prepared by a previously described procedure,40
with the 3,5-diacetyl-1,2,4-triazol bis(4-cyclohexylthiosemi-
carbazone) ligand (0.232 g, 0.5 mmol) in toluene, in the pres-
ence of Et3N, in 1 : 1 molar ratios. The reaction mixture was
stirred for 2 h at room temperature. The resulting orange solution
was ﬁltered and left to stand at ambient temperature for two
days. The yellow-orange microcrystalline solid formed was
ﬁltered, washed several times with hot water, recrystallized from
ethanol and ﬁnally dried in vacuo.
Yield (70%), mp 187 °C. Elemental analysis found, C, 49.90;
H, 5.50; N, 13.60; S, 6.50; C38H46N9S2PPt requires C, 49.70; H,
5.00; N, 13.70; S, 7.00%. MS (FAB+ with mNBA matrix) m/z
918.5 for [Pt(H3L
1)PPh3]
+. IR (KBr pellets): n/cm−1 3248, 3181
(s, NH); 2924, 2848 (s, CH), 1513 (s, CN), 856 (w, CS-thio-
amide IV band). 1H NMR (300.14 MHz, DMSO-d6): δ (ppm)
12.20 (s, 2NH, 1H); 7.92–7.89 (d, 4NH, 2H), 7.60–7.45 (m, aro-
matic protons, 15H); 4.33–4.29, 4.10 (m, CH-cyclohexyl, 2H),
3.30 and 2.5 (s, CH3-triazol, 3H), 1.85, 1.70 (m, CH2 equatorial-
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cyclohexyl, 10H), 1.40–1.20 (m, CH2 axial-cyclohexyl, 10H).
31P NMR (121.50 MHz, CDCl3): δ (ppm) 11.20 (PPh3).
Method 2. Triphenylphosphine (0.007 g, 0.04 mmol) and tri-
ethylamine base (1 mL) were added to a suspension of com-
pound 1 (0.026 g, 0.02 mmol) in toluene (20 mL) to give a clear
solution, which was stirred at room temperature for 12 h. The
orange solid that precipitated was ﬁltered, washed with hot water
and Et2O and dried in vacuo.
Crystallization in ethanol allowed us to isolate single red crys-
tals, which were studied by X-ray diffraction techniques.
[(PPh3)Pd(H2L
1)PdCl], 4. To a solution of complex 2 (0.15 g,
0.2 mmol) in toluene was added PdCl2(PPh3)2 metallic salt
(0.09 g, 0.02 mmol), in the presence of Et3N. The reaction
mixture was stirred for 2 h at room temperature. The resulting
orange solution was ﬁltered and left to stand at ambient temp-
erature for two days. The yellow-orange microcrystalline solid
formed was ﬁltered, washed several times with hot water, recrys-
tallized from ethanol and ﬁnally dried in vacuo.
Yield (32%), mp 128 °C. Elemental analysis found, C, 59.10;
H, 5.30; N, 8.05; S, 4.10; C38H44ClN9S2PPd2·2PPh3 requires C,
59.40; H, 4.95; N, 8.45; S, 4.30%. MS (FAB+ with mNBA
matrix) m/z 936.3 for [(M − Cl) + H]+. IR (KBr pellets): n/cm−1
3213 (s, NH); 2927, 2851 (s, CH), 1523 (s, CN), 859 (w,
CS-thioamide IV band). 1H NMR (300.14l MHz, DMSO-d6):
δ (ppm) 12.70 (s, 2NH); 8.30–8.25 (d, 4NH), 8.05–7.80 (m,
aromatic protons); 4.45, 4.40 (s, CH-cyclohexyl), 2.90 and 2.75
(s, CH3-triazol), 1.90 (m, CH2 equatorial-cyclohexyl), 1.50 (m,
CH2 axial-cyclohexyl).
31P NMR (121.50 MHz, CDCl3): δ
(ppm) 29.00 (PPh3).
Single orange crystals, suitable for single crystal X-ray diffrac-
tion analysis, were grown by slow evaporation from a dimethyl-
sulfoxide–pentane (3 : 1) solution.
Crystallography
Data were collected on a Bruker X8 APEX II CCD (compounds
2, 3 and 4). Crystallographic data and selected interatomic dis-
tances and angles are listed in Table 1. For all compounds, the
software package SHELXTL was used for space group determi-
nation, structure solution, and reﬁnement.41 The structures were
solved by direct methods, completed with difference Fourier
syntheses, and reﬁned with anisotropic displacement parameters.
All of the compounds here presented crystallize with solvent
molecules: compound 2 contains a disordered ethanol molecule
occupying two alternative positions. Compound 3 contains an
ethanol molecule, and compound 4 crystallizes with one partially
disordered DMSO molecule and one n-pentane molecule.
In vitro antiproliferative activity
The human cancer cells A2780, A2780cisR and NCI-H460 were
grown in an RPMI-1640 medium supplemented with 10% foetal
bovine serum (FBS) and 2 mM L-glutamine in an atmosphere of
5% CO2 at 37 °C. The human cancer cells MCF-7 were grown
in an EMEM medium with 2 mM L-glutamine and Earle’s BBS
(adjusted with 1.5 g L−1 NaHCO3, 0.1 mM nonessential amino
acids and 1 mM sodium pyruvate) and supplemented with 10%
FBS and 0.01 mg mL−1 bovine insulin in an atmosphere of 5%
CO2 at 37 °C. The human cancer cells Hep-G2 were grown in an
EMEM medium supplemented with 10% FBS in an atmosphere
of 5% CO2 at 37 °C.
Cell proliferation was evaluated by the sulforhodamine B
assay. Cells were plated in 96-well sterile plates at a density of
1.5 × 104 (for NCI-H460), 1 × 104 (for MCF-7 and Hep-G2) or
4 × 103 (for A2780 and A2780cisR) cells per well with 100 μL
of medium and were then incubated for 24 h. After attachment to
the culture surface the cells were incubated with various concen-
trations of the compounds tested freshly dissolved in DMSO
(1 mg mL−1) and diluted in the culture medium (DMSO ﬁnal
concentration 1%) for 48 h (for NCI-H460 and Hep-G2) or 96 h
(for A2780, A2780cisR and MCF-7). The cells were ﬁxed by
adding 50 μL of 30% trichloroacetic acid (TCA) per well. The
plates were incubated at 4 °C for 1 h and then washed ﬁve times
with distilled water. The cellular material ﬁxed with TCA was
stained with 0.4% sulforhodamine B dissolved in 1% acetic acid
for 10 min. Unbound dye was removed by rinsing with 0.1%
acetic acid. The protein-bound dye was extracted with 10 mM
unbuffered Tris base for determination of optical density (at
515 nm) in a Tecan Ultra Evolution spectrophotometer.
The normal cells (LLC-PK1) were grown in 199 medium sup-
plemented with 3% FBS and 1.5 g L−1 of sodium bicarbonate in
an atmosphere of 5% CO2 at 37 °C. Cell proliferation was
evaluated by the sulforhodamine B assay. Cells were plated in
96-well sterile plates at a density of 1 × 104 cells per well with
100 μL of medium and were then incubated for 24 h. After
attachment to the culture surface the cells were incubated with
various concentrations of the compounds tested freshly dissolved
in DMSO (1 mg mL−1) and diluted in the culture medium
(DMSO ﬁnal concentration 1%) for 48 h at 37 °C. The cells
were ﬁxed by adding 50 μL of 30% TCA per well. The plates
were incubated at 4 °C for 1 h and then washed ﬁve times with
distilled water. The cellular material ﬁxed with TCAwas stained
with 0.4% sulforhodamine B dissolved in 1% acetic acid for
10 min. Unbound dye was removed by rinsing with 0.1% acetic
acid. The protein-bound dye was extracted with 10 mM unbuf-
fered Tris base for determination of optical density (at 515 nm)
in a Tecan Ultra Evolution spectrophotometer.
The effects of complexes were expressed as corrected percen-
tage inhibition values according to the following equation:
%inhibition ¼ ½1 ðT=CÞ  100
where T is the mean absorbance of the treated cells and C the
mean absorbance in the controls.
The inhibitory potential of compounds was measured by
calculating concentration–percentage inhibition curves, these
curves were adjusted to the following equation:
E ¼ Emax=½1þ ðIC50=CÞn
where E is the percentage inhibition observed, Emax is the
maximal effect, IC50 is the concentration that inhibits 50% of
maximal growth, C is the concentration of compounds tested and
n is the slope of the semi-logarithmic dose–response sigmoid
curves. This non-linear ﬁtting was performed using GraphPad
Prism 2.01, 1996 software.42
For comparison purposes, the antiproliferative activity of
cisplatin was evaluated under the same experimental conditions.
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All compounds were tested in two independent studies with tri-
plicate points. These experiments were carried out at the Unidad
de Evaluación de Actividades Farmacológicas de Compuestos
Químicos (USEF), Universidad de Santiago de Compostela.
DNA-binding experiments
CT-DNA stock solution was prepared by dissolving the lyophi-
lized sodium salt in Tris-buffer (NaCl 50 mM, Tris-HCl 5 mM,
pH was adjusted to 7.3 with NaOH 0.5 M) by stirring at 4 °C for
2 days. The CT-DNA solution was standardized spectrophotome-
trically43 by using its known molar absorption coefﬁcient at
260 nm (6600 M−1 cm−1). The ratio of UV absorbance at 260
and 280 nm, A260/A280, was ca. 1.9, indicating that the DNAwas
sufﬁciently free of protein. Stock solutions were kept frozen
until the day of the experiment.
Concentrated stock solutions (5 × 10−3 M) of both the ligand
and complex 1 were prepared by dissolving each one of the com-
pounds in DMSO. From these stock solutions, for all experi-
ments the desired concentration of the compound was achieved
by dilution with Tris-buffer (NaCl 50 mM, Tris-HCl 5 mM, pH
was adjusted to 7.3 with NaOH 0.5 M) to give homogeneous
solutions with DMSO contents of less than 2.5%.
In order to prepare the adducts with double-stranded
CT-DNA, to a mixture of a ﬁxed amount of CT-DNA (1.25 ×
10−4 M) in Tris buffer were added predetermined quantities of
the desired compound solution to achieve different R values (R =
[CT-DNA]/[compound]). The mixtures were incubated for
10 min at 37 °C, and their UV-vis absorption spectra were
recorded, at room temperature, in the wavelength interval of
240–400 nm.
Conclusions
In summary, a new family of Pt(II) and Pd(II) compounds, 1–4,
containing the 3,5-diacetyl-3,5-triazol bis(4-cyclohexyl thiosemi-
carbazone) ligand, H5L
1, as a platform for metal arrangement,
has been successfully prepared and characterized.
This study has identiﬁed both the free ligand H5L
1 and the
Pt(II) dimer complex 1 as having promising antiproliferative
activity since they are capable of not only circumventing cis-
platin resistance in A2780cisR cells but they also exhibit anti-
proliferative activity against lung NCI-H460 cancer cells. The
ligand also exhibits antiproliferative activity against breast
(MCF-7) cancer cells. Moreover, it is important to note that
these two compounds exhibit, in vitro, very low renal toxicity
with respect to cisplatin.
Taking into account that these compounds are active in
A2780cisR cisplatin resistant cells and, moreover, both ligands
and platinum(II) complexes do efﬁciently interact with CT-DNA
by inducing structural changes on DNA secondary structure
different from those induced by cisplatin, it is most likely that
part of the biochemical mechanism of action of these bis(thio-
semicarbazone) compounds involves groove binding. The com-
pounds synthesized here are neutral, aromatic and hydrophobic
molecules and therefore should tend to accumulate within the
lypophilic DNA grooves.
The studies reported here constitute a good example of how
small changes in molecular structure lead to profound differ-
ences in biological activity. In our opinion, the conjunction of
serendipity and rational design (probability) plays a signiﬁcant
role in cancer drug discovery due to the existence of several very
speciﬁc factors to be considered.
Based on these results the H5L
1 ligand and the platinum
dimer complex 1, reported here, represent a valuable lead in the
development of new anticancer chemotherapeutic agents capable
of improving antitumor activity and reducing nephrotoxicity.
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